Article

Safety and Efficacy of Red Yeast Rice (Monascus purpureus) as an Alternative Therapy for Hyperlipidemia.

Matthew Klimek and Adeleye Ogunkanmi are postdoctoral fellows at Rutgers University Ernest Mario School of Pharmacy in Piscataway, New Jersey. Shan Wang is a clinical pharmacist at Winthrop University Hospital in Mineola, New York.
P&T (Impact Factor: 1.07). 07/2009; 34(6):313-27.
Source: PubMed

ABSTRACT Red yeast rice is a Chinese fermented rice product (Monascus purpureus) that some have claimed improves blood circulation by decreasing cholesterol and triglyceride levels in humans. The supplement contains naturally occurring monacolin K, the active ingredient found in Merck's prescription agent lovastatin (Mevacor). Lovastatin is associated with various adverse effects such as myopathy and abnormal liver function test results, which can lead to serious problems if patients are not monitored and treated. The inclusion of lovastatin in red yeast rice and the lack of dietary supplement regulation by the FDA raise safety concerns for health care professionals as well as for patients. Studies have shown that red yeast rice products can be beneficial in lowering serum cholesterol levels, but they are not without risk. Furthermore, product uniformity, purity, labeling, and safety cannot be guaranteed.

0 Followers
 · 
112 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sulfurous mineral water and its main active ingredient sodium hydrosulfide (NaHS) are major sources of H2S. The present study aimed to explore their protective effect on one of the serious long-term complications of diabetes; diabetic nephropathy.
    Pharmacological reports: PR 02/2015; 67(1). DOI:10.1016/j.pharep.2014.08.001 · 2.17 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Red yeast rice (i.e., rice fermented with Monascus spp.) is currently sold via the Internet as a dietary supplement. Claims state that red yeast rice has the ability to lower blood cholesterol concentrations. The mechanism of action is well characterised because the red yeast rice constituent monacolin K is identical with lovastatin, an inhibitor of the hydroxymethylglutaryl-CoA (HMG-CoA) reductase that is used in many cholesterol-lowering medicinal products. The aim of this article is to evaluate the properties of red yeast rice products that are marketed via the Internet. Three out of five analyzed products may reach the daily dosage of 10 mg lovastatin, which is necessary for the substantiation of health claims on the maintenance of normal blood LDL-cholesterol levels as suggested by the Scientific Opinion of the European Food Safety Authority. 10 mg is also the starting dosage of medicinal lovastatin products on the German market. From a regulatory standpoint, red yeast rice products would rather have to be sold as medicinal products than as food supplements as they clearly exhibit a pharmacological action that is comparable to approved statin-containing medicinal products. This also implies potential adverse effects and interactions, about which the consumer is insufficiently informed in the case of food supplements. The lack of control over the Internet market is evidenced by the fact that four of the tested products were not marketable in conventional trade in Germany due to violations of labelling rules.
    Deutsche Lebensmittel-Rundschau: Zeitschrift für Lebensmittelkunde und Lebensmittelrecht 07/2012; 108(7):357-360. · 0.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Red yeast rice (RYR) is a Chinese herbal supplement produced by fermenting white rice with the yeast, Monascus purpureus. The Chinese have used RYR to flavor, color, and preserve foods and as a traditional medicine for many years. In the USA, RYR has been used as an alternative to statin therapy in treating patients with mild to moderate hypercholesterolemia. RYR contains a variety of monacolins, which inhibit hydroxymethylglutaryl-coenzyme A (HMG CoA) reductase, the rate-limiting step in cholesterol synthesis. Consumption of RYR has increased recently especially among patients who might be intolerant to standardized therapy due to statin-associated myalgia (SAM). Several clinical trials have shown RYR to be safe, effective, and well tolerated; however, the studies are small and of short duration. The US Food and Drug Administration has prohibited the sale of all RYR products containing monacolin K, which is chemically identical to lovastatin, because it is considered an unapproved drug. However, many RYR supplements continue to remain on the market and lack standardization and quality control.
    Current Atherosclerosis Reports 04/2015; 17(4):495. DOI:10.1007/s11883-015-0495-8 · 3.06 Impact Factor

Full-text (2 Sources)

Download
18 Downloads
Available from
Jun 10, 2014